Samuel M. Silver, MD, PhD, and Al B. Benson III, MD, FACP, FASCO, on 20 Years of Improving Cancer Care Together

0 seconds of 0 secondsVolume 90%

00:00

Samuel M. Silver, MD, PhD, and Al B. Benson III, MD, FACP, FASCO, on 20 Years of Improving Cancer Care Together: A Clinical Perspective

2015 NCCN Annual Conference

Samuel M. Silver, MD, PhD, of the University of Michigan Comprehensive Cancer Center, and Al B. Benson III, MD, FACP, FASCO, of Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discuss the evolution of NCCN Guidelines, which are available free online, and the components that make them effective: a multidisciplinary approach, the participation of patient advocates, consistency, and affordability of the evidence.

William G. Wierda, MD, PhD, on Updates to the Management of CLL

William G. Wierda, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses the latest information on managing CLL and his optimism that a cure is in sight.

Prostate Cancer

Andrew J. Armstrong, MD, ScM

Andrew J. Armstrong, MD, ScM, on New Treatment Options in Castration-Resistant Prostate Cancer

Andrew J. Armstrong, MD, ScM, of Duke Cancer Institute, discusses the recent practice-changing landmark studies that showed significant increases in survival for men with castration-resistant prostate cancer and led to updates in the NCCN Guidelines for this disease.

Leukemia

Jerald P. Radich, MD

Jerald P. Radich, MD, on Treatment Milestones in CML: Stay the Course or Change Therapy?

Jerald P. Radich, MD, of the Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance discusses the evolution in treating and monitoring CML and whether monitoring at 3 and 6 months will ultimately prove useful.

Gynecologic Cancers

Wui-Jin Koh, MD

Wui-Jin Koh, MD, on Making NCCN Guidelines Relevant Around the Globe

Wui-Jin Koh, MD, of the Fred Hutchinson Cancer Research Center and the Seattle Cancer Care Alliance, discusses the program to adapt NCCN guidelines to regions of the world with different resource availability. The first guideline to be adapted in this way is for cervical cancer, which is prevalent in the developing world.

Issues in Oncology

Mary Lou Smith, JD, MBA

Mary Lou Smith, JD, MBA, on the Value of NCCN Guidelines to Patients and Their Advocates

Mary Lou Smith, JD, MBA, of the Research Advocacy Network, discusses, from the perspective of a patient advocate, the value of the NCCN guidelines and the impact they have made on cancer care.

Apr

Today In Oncology

Samuel M. Silver, MD, PhD, and Al B. Benson III, MD, FACP, FASCO, on 20 Years of Improving Cancer Care Together: A Clinical Perspective

Related Videos

William G. Wierda, MD, PhD, on Updates to the Management of CLL

Andrew J. Armstrong, MD, ScM, on New Treatment Options in Castration-Resistant Prostate Cancer

Jerald P. Radich, MD, on Treatment Milestones in CML: Stay the Course or Change Therapy?

Wui-Jin Koh, MD, on Making NCCN Guidelines Relevant Around the Globe

Mary Lou Smith, JD, MBA, on the Value of NCCN Guidelines to Patients and Their Advocates

NK Cells Complexed With Bispecific Antibody May Be of Benefit to Patients With Lymphoma

Study Identifies Biologic Reasons for Selective Benefit of PARP Inhibitors

Hypofractionation vs Conventional Fractionation in Patients With Breast Cancer Planning Breast Reconstruction

Rates of Breast, CRC Screenings Almost Four Times Higher Than Lung Cancer Screenings

Comparing Biopsy Techniques for Prostate Cancer Detection